{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-23-000064","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.424852+00:00","generated_at":"2026-06-08T04:11:08.324602+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Biohaven Q3 net loss $102.6M ($1.50/share); cash $495M after public offering; pipeline advances","bullets":["Net loss of $102.6M ($1.50/share) vs $68.9M ($1.75/share) in Q3 2022; non-GAAP adjusted net loss $98.1M ($1.44/share).","Cash, cash equivalents and securities $495M as of Oct 5, 2023, including $242M net from public offering of 11.76M shares at $22.","BHV-1300 IgG degrader showed >90% IgG reduction in non-human primates; IND submission on track for 2023.","BHV-7000 Phase 1 EEG study confirmed CNS target engagement; Phase 3 focal epilepsy trial to start in 2023.","Completed enrollment in Phase 3 study of taldefgrobep alfa in SMA; troriluzole MAA under EMA review."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-23-000064","json":"https://secwatch.observer/filing/0001935979-23-000064.json","markdown":"https://secwatch.observer/filing/0001935979-23-000064.md","text":"https://secwatch.observer/filing/0001935979-23-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000064/0001935979-23-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000064/bhvn-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:11:08.324602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}